INTRODUCTION: Lecanemab has shown promise in treating early Alzheimer's disease (AD), but its safety and efficacy in Chinese populations remain unexplored. This study aimed to evaluate the safety and 6-month clinical outcomes of lecanemab in Chinese patients with mild cognitive impairment (MCI) or mild AD. METHODS: In this single-arm, real-world study, participants with MCI due to AD or mild AD received biweekly intravenous lecanemab (10 mg/kg). The study was conducted at Hainan Branch, Ruijin Hospital Shanghai Jiao Tong University School of Medicine. Patient enrollment and baseline assessments commenced in November 2023. Safety assessments included monitoring for amyloid-related imaging abnormalities (ARIA) and other adverse events. Clinical and biomarker changes from baseline to 6 months were evaluated using cognitive scales (mini-mental state examination [MMSE], montreal cognitive assessment [MoCA], clinical dementia rating-sum of boxes [CDR-SB]), plasma biomarker analysis, and advanced neuroimaging. RESULTS: A total of 64 patients were enrolled in this ongoing real-world study. Safety analysis revealed predominantly mild adverse events, with infusion-related reactions (20.3%, 13/64) being the most common. Of these, 69.2% (9/13) occurred during the initial infusion and 84.6% (11/13) did not recur. ARIA-H (microhemorrhages/superficial siderosis) and ARIA-E (edema/effusion) were observed in 9.4% (6/64) and 3.1% (2/64) of participants, respectively, with only two symptomatic cases (one ARIA-E presenting with headache and one ARIA-H with visual disturbances). After 6 months of treatment, cognitive scores remained stable compared to baseline (MMSE: 22.33 ± 5.58 vs . 21.27 ± 4.30, P = 0.733; MoCA: 16.38 ± 6.67 vs . 15.90 ± 4.78, P = 0.785; CDR-SB: 2.30 ± 1.65 vs . 3.16 ± 1.72, P = 0.357), while significantly increasing plasma amyloid-β 42 (Aβ42) (+21.42%) and Aβ40 (+23.53%) levels compared to baseline. CONCLUSIONS: Lecanemab demonstrated a favorable safety profile in Chinese patients with early AD. Cognitive stability and biomarker changes over 6 months suggest potential efficacy, though high dropout rates and absence of a control group warrant cautious interpretation. These findings provide preliminary real-world evidence for lecanemab's use in China, supporting further investigation in larger controlled studies. REGISTRATION ClinicalTrials.gov , NCT07034222.
Humans ; Alzheimer Disease/drug therapy* ; Male ; Female ; Aged ; Middle Aged ; Cognitive Dysfunction/drug therapy* ; Aged, 80 and over ; Amyloid beta-Peptides/metabolism* ; Biomarkers ; East Asian People

Objective:To explore the influencing factors of medical adhesive-related skin injury (MARSI) at the site of central venous catheter (CVC) placement in ICU patients.Methods:Using the convenient sampling method, a total of 479 patients who were admitted to General Surgery ICU and Vascular Surgery ICU of a Class Ⅲ Grade A hospital in Beijing were selected as the research objects from January to November 2019. A self-designed data collection form was used for investigation. Binomial Logistic regression was used to analyze the influencing factors of MARSI at the CVC placement site in ICU patients.Results:The incidence of MARSI at the CVC placement site in ICU patients was 6.89% (33/479) . Binary logistic regression analysis showed that age, length of stay in ICU, NRS 2002 score and skin edema were risk factors for MARSI at the CVC placement site in ICU patients ( OR=1.033, 1.005, 4.221, 13.107; P<0.05) . Serum albumin and normal skin color were protective factors for MARSI at the CVC placement site in ICU patients ( OR=0.876, 0.052; P<0.01) . Conclusions:Nurses should strengthen the evaluation and intervention of ICU patients with risk factors for MARSI to effectively prevent the occurrence of MARSI at the CVC placement site.

During the treatment of critically ill patients, the application of enteral nutrition is increasingly widespread, but its series of complications also deserve attention. Among them, the incidence of intestinal nutrition intolerance is as high as 30.5%-75%. In recent years, researchers at home and abroad have carried out researches on the evaluation and intervention of intestinal nutrition intolerance. The application of the research results has improved the nutritional tolerance of patients. In order to provide more comprehensive and new research information, the following review is now conducted.

The analysis on regularity of comparability among famous physician's prescriptions for treating chest pain since the Han Dynasty will be helpful to treat chest pain and develop new herbs.The Chinese Medicine Auxiliary System (V2.5) was used to analysis the regularity of comparability by inputting the most famous 101 prescriptions for the treatment of chest pain from the Han Dynasty to Qing Dynasty.The results showed that the most common single drugs were cassia twig,40 times (39.6％).The most common couplet medicines were licorice and poria cocos,21 times (20.8％).The most common triangle medicines were ginger,pinellia,and cassia twig,13 times (12.9％).The most common drug combination based on association rules was the combination of cassia twig,peucedani radix→ginger (confidence level of 0.909 1).The core drugs based on complex network was cassia twig,licorice,and etc.New prescription combinations based on the entropy method were 11 new prescriptions including allium,cassia twig,poria,and almonds.It was concluded that there were regularity of comparability in ancient prescriptions for treating chest pain.Approaching and developing medicine for the treatment of chest pain should be from the following 6 points.The priority choice of single drug was cassia twig,and etc.The priority choice of couplet medicines was licorice and poria cocos,etc.The priority choice of triangle medicines was ginger,pinellia,cassia twig,and etc.The combination of high correlation should be chosen in treating chest pain,such as cassia twig,peucedani radix→ginger,and etc.The core drugs are necessary.In the warming yang method,cassia twig is the core drug and ginger is the auxiliary drug,and etc.New prescription combination,such as allium,cassia twig,poria,almonds,and etc.should be applied.